Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML

NCT02875093 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

23

Enrollment

INDUSTRY

Sponsor class

Stopped Study Termination

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: ADI-PEG 20
DRUG: Cytarabine

Sponsor

Polaris Group